Abstract:
:Atezolizumab was the first immune checkpoint inhibitor (ICI) to be introduced as a first-line treatment option for extensive-stage small cell lung cancer (ES-SCLC), in combination with carboplatin and etoposide (CE) chemotherapy. However, SCLC treatment options after progression to first-line chemotherapy are limited, warranting the readministration of previously used drugs. In combination with atezolizumab, CE readministration may theoretically be effective, based on two tentative mechanisms: its additive and synergistic effects on cytotoxic chemotherapy. The additive effect is based on the IFCT-1603 trial in which the Kaplan-Meier estimates of both progression-free survival (PFS) and overall survival (OS) in the atezolizumab group exhibited a tail plateau in the selected population. Conversely, an anti-PD-L1 antibody synergistic effect on platinum compounds was assessed in a preclinical study, which was reinforced by clinical data. Thus, atezolizumab in combination with CE may be a treatment option in heavily treated patients. Here, we describe the first case of a heavily treated ES-SCLC patient treated with chemoimmunotherapy, resulting in a partial response and a durable PFS. KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY AND WHAT THIS STUDY ADDS: CE readministration with atezolizumab may be effective based on two tentative mechanisms. Additive and synergistic effects of atezolizumab on CE have been previously suggested via a clinical trial and preclinical study, respectively. This is reflected in the current case in clinical settings.
journal_name
Thorac Cancerjournal_title
Thoracic cancerauthors
Kataoka N,Kunimatsu Y,Tachibana Y,Sugimoto T,Sato I,Tani N,Ogura Y,Hirose K,Takeda Tdoi
10.1111/1759-7714.13588subject
Has Abstractpub_date
2020-09-01 00:00:00pages
2740-2742issue
9eissn
1759-7706issn
1759-7714journal_volume
11pub_type
相关文献
Thoracic Cancer文献大全abstract:BACKGROUND:Our previous study showed that SUMO1 expression is closely related to progression in non-small cell lung cancer (NSCLC); however, the function of SUMO1 in NSCLC has not yet been well elucidated. METHODS:SUMO1 was enhanced or silenced in two NSCLC cell lines by using either forced SUMO1 expression or short h...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12895
更新日期:2019-01-01 00:00:00
abstract::For refractory or resistant small cell lung cancer (SCLC), there is no standard treatment. We report a case of refractory SCLC achieving complete remission and then developing fatal interstitial pneumonitis after treatment with single-agent nab-paclitaxel. The relevant literature has also been reviewed. In terms of ef...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/j.1759-7714.2011.00086.x
更新日期:2012-02-01 00:00:00
abstract:BACKGROUND:Non-small-cell lung cancer (NSCLC) is the most lethal type of cancer. Long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) have been identified as crucial regulators in the development of NSCLC. The aim of our study was to explore the molecular mechanism of SNHG1 to enable better treatment for NSCLC patient...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13256
更新日期:2020-02-01 00:00:00
abstract::A mediastinal germ cell tumor with a sarcomatous component is extremely rare and is accompanied by a poor prognosis. Clinical and radiologic diagnosis is very difficult. Herein, we report a rare case of anterior mediastinal malignant teratoma containing a growing liposarcomatous component and detail the diagnostic pro...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12553
更新日期:2018-01-01 00:00:00
abstract:BACKGROUND:To investigate the correlation between mesenchymal-epithelial transition factor (C-Met) and human epidermal growth receptor 2 (HER2) protein expression in primary lung adenocarcinoma tissues. METHOD:A total of 1479 resected primary lung adenocarcinoma patients were enrolled in the present study for detectin...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12595
更新日期:2018-04-01 00:00:00
abstract:BACKGROUND:Increasing evidence has demonstrated that circular RNAs (circRNAs) may play an important role in oncogenesis and tumor development; however, their role in lung adenocarcinoma (LUAD) remains unclear. We identified the differentially expressed circRNAs in LUAD and investigated the potential mechanisms for canc...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12761
更新日期:2018-08-01 00:00:00
abstract::The extravasation of cytotoxic agents into subcutaneous tissue is a serious complication of chemotherapy. Unfortunately, if such extravasation occurs into the pleural space, limited data is available to guide appropriate management. We present the first report in the literature of video-assisted thoracoscopy combined ...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.12430
更新日期:2017-07-01 00:00:00
abstract:BACKGROUND:Scutellarin (SCU), a flavonoid isolated from Erigeron breviscapus (Vant.) Hand.-Mazz., increases autophagy and apoptosis in the adenocarcinoma A549 cell line, which is resistant to cisplatin. However, whether SCU alone has antitumor activity against non-small cell lung cancer (NSCLC) is unknown. METHODS:Cel...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12962
更新日期:2019-03-01 00:00:00
abstract:BACKGROUND:Malignant pleural mesothelioma (MPM) is a rare but aggressive tumor that originates from the pleura and has a poor prognosis. Eligible patients can benefit from surgery, but their survival is affected by many factors. Therefore, we created a graphic model that could predict the prognosis of surgically treate...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13063
更新日期:2019-05-01 00:00:00
abstract:BACKGROUND:Despite recent advances in treating non-small cell lung cancer (NSCLC) with immune checkpoint inhibitors (ICIs), their role in ALK-positive NSCLC patients is unclear. We investigated the efficacy of ICIs in patients with ALK-positive NSCLC. METHODS:Between 2011 and 2018, a total of 14 ALK-positive NSCLC pat...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13195
更新日期:2019-11-01 00:00:00
abstract::A squamous cell lung cancer patient was treated with pneumonectomy. A recurrent lung cancer (adenocarcinoma) was found 45 months later and successfully biopsied and treated with microwave ablation. After 18 months of follow up, no evidence of tumor recurrence was observed. ...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12244
更新日期:2016-01-01 00:00:00
abstract:BACKGROUND:Plasmid construction of small fragments of interest (such as insertion of small fragment marker genes, expression of shRNA, siRNA, etc) is the basis of many biomolecular experiments. Here, we describe a method to clone short DNA into vectors by polymerase chain reaction (PCR), named one-step PCR cloning. Our...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13660
更新日期:2020-11-01 00:00:00
abstract::SMARCA4-deficient thoracic sarcoma (SMARCA4-DTS) is a new clinical entity characterized by SMARCA4 inactivation and has a dismal prognosis because of rapid growth. Effective treatments for SMARCA4-DTS have not yet been developed. Most recently, anti-programmed cell death 1 receptor (PD-1) blockade has been effective f...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.13215
更新日期:2019-12-01 00:00:00
abstract:BACKGROUND:The current study aimed to determine the oncological efficacy and surgical safety of multiple pulmonary resections (MPRs) after prior curative surgery for local regional recurrent or second primary lung cancers. METHODS:All cases of lung cancer included in our prospective database between January 2000 and J...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12790
更新日期:2018-08-01 00:00:00
abstract:BACKGROUND:In cases of EGFR-tyrosine kinase inhibitor (TKI) failure, re-biopsy may be useful to understand resistance mechanisms and guide further treatment decisions. However, performing re-biopsy is challenging because of several hurdles. We assessed the feasibility of re-biopsy in advanced non-small cell lung cancer...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12762
更新日期:2018-07-01 00:00:00
abstract:BACKGROUND:To distinguish early-stage lung cancer from benign disease in pulmonary nodules, especially lesions with ground-glass opacity (GGO), we assessed gene mutations of ctDNA in peripheral blood using targeted next-generation sequencing (NGS). METHODS:Single pulmonary nodule patients without mediastinal lymph nod...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13741
更新日期:2020-11-16 00:00:00
abstract:BACKGROUND:This study was conducted to evaluate the clinical utility of the oHSV1-hTERT-GFP circulating tumor cell (CTC) detection method in the peripheral blood of patients with lung cancer by comparing its sensitivity to the CellSearch CTC detection method. METHODS:The oHSV1-hTERT-GFP and CellSearch CTC detection me...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12526
更新日期:2018-01-01 00:00:00
abstract::Enhanced recovery after surgery (ERAS) is a multiprofessional, multidisciplinary and evidence-based program that aims to reduce complications, improve overall prognosis, shorten hospital stays, and promote fast recovery following major surgery. Nurses play a crucial role in the successful implementation of the ERAS pr...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13372
更新日期:2020-04-01 00:00:00
abstract::Almost all epidermal growth factor receptor (EGFR)-mutant lung cancers develop resistance to EGFR-tyrosine kinase inhibitors. Several mechanisms for this acquired resistance have been identified, including development of an EGFR T790M mutation, MET amplification, hepatocyte growth factor overexpression, loss of phosph...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.12484
更新日期:2017-11-01 00:00:00
abstract::This report describes the surgical management of a male patient with early-stage lung cancer who underwent thoracoscopic completion right lower lobectomy after previously undergoing sublobar resection for multifocal ground glass nodules of the lung. Perioperative considerations associated with the management of dense ...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.13036
更新日期:2019-05-01 00:00:00
abstract::Selected patients with non small-cell lung cancer (NSCLC) with mediastinal lymph node involvement may have a survival benefit from surgical resection, particularly if mediastinal nodal down-staging occurs after induction therapy and complete resection is achieved with lobectomy. Accurate re-staging of the mediastinum ...
journal_title:Thoracic cancer
pub_type: 杂志文章,评审
doi:10.1111/j.1759-7714.2011.00097.x
更新日期:2012-05-01 00:00:00
abstract:BACKGROUND:Achaete-scute homolog 1 (ASCL1) is a basic helix-loop-helix transcription factor and is essential in the differentiation of neuroendocrine cells and neural tissues. ASCL1 is frequently overexpressed in small cell lung cancer (SCLC) and plays a crucial role in the pathogenesis of SCLC. METHODS:This study was...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13212
更新日期:2020-01-01 00:00:00
abstract:BACKGROUND:The standard of care for fit locally advanced non-small cell lung cancer (NSCLC) patients is concurrent chemoradiotherapy (CCRT). However, in a subset of patients with lung adenocarcinoma with mutant EGFR (LA-mEGFR), the role of EGFR-tyrosine kinase inhibitors (TKIs) is not clear. We compared CCRT versus TKI...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12847
更新日期:2018-11-01 00:00:00
abstract::Both crizotinib and osimertinib have been reported to have an adverse effect of interstitial pneumonitis in the treatment of non-small cell lung cancer (NSCLC). Here, we report the case of a 60-year-old male patient with advanced NSCLC resistant to osimertinib. Crizotinib was administered in combination with osimertin...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.13785
更新日期:2021-01-12 00:00:00
abstract:BACKGROUND:We performed a retrospective analysis to compare the efficacy of whole brain radiotherapy (WBRT) combined with temozolomide (TMZ) versus WBRT alone as first-line treatment for brain metastases (BM). METHODS:Seventy-eight non-small cell lung cancer patients with BM were observed, including 45 patients who re...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12795
更新日期:2018-09-01 00:00:00
abstract:BACKGROUND:The important role of angiogenesis displaying in tumor development and metastasis has been generally realized. Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and endostatin (ES) are critical members of angiogenesis modulating the balance between pro-angiogenenic and anti-ang...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12202
更新日期:2015-07-01 00:00:00
abstract:BACKGROUND:Several studies have previously demonstrated the survival benefit of both EGFR-TKI treatment and chemotherapy in patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations. The aim of the present study was to clarify the factors influencing the treatment sequence after failure of EGFR-TKI ther...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13360
更新日期:2020-04-01 00:00:00
abstract:OBJECTIVES:To evaluate the oncological prognosis and neurological outcomes for patients with thymic epithelial tumors (TETs) after thymectomy. METHODS:Consecutive patients with TETs who underwent thymectomy at Beijing Hospital from January 2011 to December 2018 were retrospectively enrolled into the study. Clinical, p...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13464
更新日期:2020-07-01 00:00:00
abstract:BACKGROUND:Many randomized clinical trials have demonstrated that epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are advantageous over standard chemotherapy, either as front-line treatment or as further management of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC). Howev...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12275
更新日期:2016-01-01 00:00:00
abstract::Lung cancer is globally one of the leading causes of malignant tumor-related mortality and ranks as having the highest incidence found in men and second in women. Osimertinib is a drug used to target lung cancer but its toxicity is not fully understood. Here we present a case of lung adenocarcinoma in a 78-year-old ma...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.13127
更新日期:2019-07-01 00:00:00